Biotricity Inc. (Biotricity) today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.
PRESS
Biotricity Inc. (Biotricity) today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.
Biotricity Inc. (Biotricity) today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Biotricity’s cardiac monitoring solution is the only three-channel connected solution in the world. This unique technology results in superior diagnostics, reduced patient risk, and enhanced workflow efficiency, providing improved clinical outcomes while lowering overall healthcare costs.
Biotricity Inc. (Biotricity) today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. HeartSecure represents a monumental leap forward in cardiac monitoring, providing users with unparalleled convenience, affordability, and peace of mind. By increasing access to heart monitoring and empowering individuals to take control of their cardiac health, Biotricity is helping reshape cardiac care.
Biotricity Inc. (Biotricity) has announced the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues. These collaborations position Biotricity and its partners as comprehensive providers of holistic screenings, marking a significant advancement in Biotricity’s mission to offer integrated healthcare solutions that address the complex needs of patients with multiple conditions.
Biotricity Inc. (Biotricity) announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%.
Biotricity Inc. (Biotricity) announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity’s technology suite.
